This Article Full Text Full Text (PDF) Data Supplement All Versions of this Article: 41/3/482    most recent 01.HYP.0000054976.67487.08v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zeitz, C. J. Articles by Horowitz, J. D. Search for Related Content PubMed PubMed Citation Articles by Zeitz, C. J. Articles by Horowitz, J. D. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Related Collections Biochemistry and metabolism Cardiovascular Pharmacology ACE/Angiotension receptors Hypertension - basic studies Clinical Studies Chronic ischemic heart disease Coronary circulation Receptor pharmacology

(Hypertension. 2003;41:482.)
© 2003 American Heart Association, Inc.

Scientific Contributions

Myocardial Uptake and Biochemical and Hemodynamic Effects of ACE Inhibitors in Humans

From the University of Adelaide, Department of Medicine, The Queen Elizabeth Hospital (C.J.Z., J.D.H.), Adelaide, South Australia, and St Vincent’s Institute of Medical Research and the University of Melbourne Department of Medicine (D.J.C.), Fitzroy, Victoria, Australia.

Correspondence to Prof John D. Horowitz, The Queen Elizabeth Hospital, Cardiology Unit, 28 Woodville Road, Woodville SA 5011, Australia. E-mail John.Horowitz{at}adelaide.edu.au

There is little information on the processes affecting selective tissue ACE inhibition and the implications in human subjects. We compared intravenously administered ACE inhibitors, perindoprilat and enalaprilat, for myocardial drug uptake and effects on angiotensin and bradykinin peptides versus hemodynamic effects in 25 patients with stable angina and well-preserved left ventricular systolic function. Myocardial uptake was rapid and more efficient for perindoprilat than for enalaprilat (peak content at 26±3 and 30±4 seconds, 0.58±0.12% and 0.27±0.07% of the administered dose for perindoprilat and enalaprilat, respectively, P=0.04 for difference). Both drugs caused a decrease in angiotensin (Ang) II level, an increase in Ang I level, and reduction in Ang II/Ang I ratio in arterial and coronary sinus blood. Bradykinin (BK)-(1-9) and BK-(1-8) levels increased in arterial blood and BK-(1-8) levels increased in coronary sinus blood after drug administration. Perindoprilat and enalaprilat caused a small decrease in mean arterial pressure (-3±1%, P<0.05; and -4±1%, P<0.01, respectively) and LV+dP/dt (-5.8±1.7%, P<0.01 and -4.2±2.8%, P<0.05, respectively), whereas systemic vascular resistance index was unchanged. Despite relatively cardioselective uptake of perindoprilat, both drugs had similar effects on the cardiac metabolism of angiotensin and bradykinin and on cardiac function. Under resting conditions, both drugs exerted small negative inotropic effects.

Key Words: metabolism • hemodynamics • bradykinin • angiotensin • myocardium • enalapril

This article has been cited by other articles:

				J.-C. Tardif Angiotensin-converting enzyme inhibitors and atherosclerotic plaque: a key role in the cardiovascular protection of patients with coronary artery disease Eur. Heart J. Suppl., August 1, 2009; 11(suppl_E): E9 - E16. [Abstract] [Full Text] [PDF]

				D. J. Campbell, H. Krum, and M. D. Esler Losartan Increases Bradykinin Levels in Hypertensive Humans Circulation, January 25, 2005; 111(3): 315 - 320. [Abstract] [Full Text] [PDF]

				D. J. Campbell, T. Alexiou, H. D. Xiao, S. Fuchs, M. J. McKinley, P. Corvol, and K. E. Bernstein Effect of Reduced Angiotensin-Converting Enzyme Gene Expression and Angiotensin-Converting Enzyme Inhibition on Angiotensin and Bradykinin Peptide Levels in Mice Hypertension, April 1, 2004; 43(4): 854 - 859. [Abstract] [Full Text] [PDF]